Literature DB >> 1711678

Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template.

E B Kopp1, J J Miglietta, A G Shrutkowski, C K Shih, P M Grob, M T Skoog.   

Abstract

Steady state kinetics and inhibition by a dipyridodiazepinone of the reverse transcriptase from human immunodeficiency virus type 1 (HIV) were studied using a heteropolymeric RNA template with a sequence from the authentic initiation site on the HIV genome. For addition of the first deoxynucleotide to primer, kcat/KM is 0.05 (nM-min)-1 and KM is 10 nM. When all 4 deoxynucleotide triphosphates are present and processive synthesis occurs, catalysis is less efficient; kcat/KM = .0077 (nM-min)-1 and KM = 100 nM for dATP. These results are consistent with a rate determining conformation change involved in translocation of the enzyme along the template. Inhibition by the dipyridodiazepinone BI-RG-587 is noncompetitive with respect to both nucleotide and template-primer; this compound decreases Vmax but does not affect KM. Thus, this inhibitor binds to a site distinct from the substrate binding sites with Ki of 220 nM. Inhibition by BI-RG-587 results in a uniform decrease in amount of products of all lengths rather than a shift from longer to shorter products, suggesting the inhibitor does not affect processivity of reverse transcriptase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711678      PMCID: PMC328267          DOI: 10.1093/nar/19.11.3035

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  13 in total

1.  Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.

Authors:  H E Huber; J M McCoy; J S Seehra; C C Richardson
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

Review 2.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

3.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Authors:  R Pauwels; K Andries; J Desmyter; D Schols; M J Kukla; H J Breslin; A Raeymaeckers; J Van Gelder; R Woestenborghs; J Heykants
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  Elementary steps in the DNA polymerase I reaction pathway.

Authors:  F R Bryant; K A Johnson; S J Benkovic
Journal:  Biochemistry       Date:  1983-07-19       Impact factor: 3.162

5.  Mechanism of HIV reverse transcriptase: enzyme-primer interaction as revealed through studies of a dNTP analogue, 3'-azido-dTTP.

Authors:  P S Kedar; J Abbotts; T Kovács; K Lesiak; P Torrence; S H Wilson
Journal:  Biochemistry       Date:  1990-04-17       Impact factor: 3.162

6.  Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases.

Authors:  P Huang; D Farquhar; W Plunkett
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

7.  Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases.

Authors:  H Nakane; K Ono
Journal:  Biochemistry       Date:  1990-03-20       Impact factor: 3.162

8.  An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.

Authors:  Z Debyser; R Pauwels; K Andries; J Desmyter; M Kukla; P A Janssen; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate.

Authors:  J E Reardon; W H Miller
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

10.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.

Authors:  V J Merluzzi; K D Hargrave; M Labadia; K Grozinger; M Skoog; J C Wu; C K Shih; K Eckner; S Hattox; J Adams
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

View more
  15 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Inhibition mechanisms of HIV-1, Mo-MuLV and AMV reverse transcriptases by Kelletinin A from Buccinulum corneum.

Authors:  P Orlando; G Strazzullo; F Carretta; M De Falco; P Grippo
Journal:  Experientia       Date:  1996-08-15

3.  Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.

Authors:  Dirk Jochmans; Jérôme Deval; Bart Kesteleyn; Herwig Van Marck; Eva Bettens; Inky De Baere; Pascale Dehertogh; Tania Ivens; Marcia Van Ginderen; Bertrand Van Schoubroeck; Maryam Ehteshami; Piet Wigerinck; Matthias Götte; Kurt Hertogs
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

Review 4.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

5.  Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.

Authors:  Janice D Pata; William G Stirtan; Steven W Goldstein; Thomas A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.

Authors:  Edward M Kennedy; Christina Gavegnano; Laura Nguyen; Rebecca Slater; Amanda Lucas; Emilie Fromentin; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

7.  L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.

Authors:  M E Goldman; J A O'Brien; T L Ruffing; J H Nunberg; W A Schleif; J C Quintero; P K Siegl; J M Hoffman; A M Smith; E A Emini
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S D Young; S F Britcher; L O Tran; L S Payne; W C Lumma; T A Lyle; J R Huff; P S Anderson; D B Olsen; S S Carroll
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.

Authors:  M B Kroeger Smith; C A Rouzer; L A Taneyhill; N A Smith; S H Hughes; P L Boyer; P A Janssen; H Moereels; L Koymans; E Arnold
Journal:  Protein Sci       Date:  1995-10       Impact factor: 6.725

10.  The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

Authors:  G Borkow; D Arion; M A Wainberg; M A Parniak
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.